The CPM seeks to develop clinical grade advanced molecular diagnostic tests that clearly inform clinicians and their patients of the best treatment and care options based on current scientific and clinical evidence and to conduct innovative genomic biomarker research.


In 2011, RPCI began directing significant resources toward the strategic development of the CPM. Funded by $16 million from RPCI and an additional $5.1 million in New York State funding awarded by the Western New York Regional Economic Developmental Council, the Center was established in 2012 with the launch of three genomic biomarker discovery projects and a community outreach initiative.The CPM is the region’s first resource for next-generation DNA sequencing to meet federal Clinical Laboratory Improvement Amendments (CLIA) standards and to create the infrastructure to make these cutting-edge technologies and robust analysis available to clinicians and researchers from other centers quickly and cost-effectively.

In 2013, the CPM leveraged Roswell Park’s nationally recognized strength and years of experience implementing enterprise-wide laboratory information management system (LIMS) solutions for scientific research management including multiple biobanks, a federated warehouse clinical data service center and genomics research core to create an unparalleled clinical laboratory information system (C-LIMS). With C-LIMS as the backbone, RPCI engaged additional software firms to integrate order entry and test reporting into the electronic health record and create a new genomic laboratory information system (LIS) that manages advanced molecular diagnostic testing data from multiple high throughput genomic technologies. This extendable suite of software and informatics solutions for genomic testing is also clinical grade FDA 2 CFR Part 11 compliant.  

With this infrastructure in place, the CPM proceeded to achieve New York State CLEP approval for OmniSeq Target™, its first advanced molecular diagnostic test for the therapeutic management of cancer patients with solid tumors.  OmniSeq Target™ was launched in July 2014 as part of the CPM's OmniSeq Program to initiate personalized genomic medicine in routine cancer care at RPCI, and will soon be making it available to affiliate organizations and other providers. To date, over 500 patients have received Omniseq target testing, with nearly half benefiting from personalized clinical care options.

Candace Johnson, PhD, President & CEO of RPCI maintains leadership of the Center for Personalized Medicine (CPM). She plays a vital role in interacting with the RPCI Board of Directors on what many consider one of the most important initiatives in RPCI's recent history.


The CPM maintains multiple high-throughput gene sequencers and a 1,600-processor supercomputing cluster.


The CPM can sequence more than 300 complete genomes per year and can decipher the complete genetic structure of an individual in just a few days’ time.

Equipment Includes


Located on the first floor of the RPCI Center for Genetics and Pharmacology, the CPM is 6,000 sq. ft. state-of the-art molecular laboratory that is fully integrated with IT, clinical informatics and bioinformatics teams.

Center for Genetics & Pharmacology
Roswell Park Cancer Institute
645 Virginia Street, Buffalo, NY
(computing cluster housed separately)